Giampaolo Bianchini· @BianchiniGP · X·· 23 hours agoScore70
Body · original
🔥 KEYNOTE-B49 meets its primary endpoint, but benefit seems limited to few patients
👉 ICIs benefit selected ER+/HER2− BC pts (CPS≥10, ER-low)
👉 Are ADCs better ICI partners than CT?
👉 What about PD-1/VEGF bispecifics?
➡️ Better biomarkers urgently needed!
#ESMO26
46 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA51matched by Proffered paper 2: Breast cancer, early and advanced stage
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.orgSource: Giampaolo Bianchini · x.com